Scientists probe why some breast cancers resist hormone drugs

NCT ID NCT06127979

Summary

This study aims to understand if breast cancers in women with BRCA2 gene mutations respond differently to hormone therapy before surgery compared to cancers in women without these mutations. Researchers will measure a specific protein (Ki67) in tumor samples before and after at least two weeks of treatment. The goal is to gather knowledge that may help tailor future treatments, but this study itself does not test a new cure.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Memorial Sloan Kettering Cancer Center (All Protocol Activities)

    RECRUITING

    New York, New York, 10065, United States

    Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.